Aldoro Resources Limited

ARN

Aldoro Resources Ltd. engaged in the exploration and development of minerals. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2018-09-13. The firm has a portfolio of critical mineral projects, including rare earth, niobium, lithium, rubidium and base metal projects. Its project is the Kameelburg REE/Niobium Carbonatite Project in Namibia. Its other projects are based in Western Australia, including the Wyemandoo lithium-rubidium project, the Niobe lithium-rubidium-tantalum Project and the Narndee Igneous Complex in Western Australia. The Wyemandoo critical metal pegmatite project comprises four exploration licenses (E57/1017, E58/571, E58/555 and E59/2431) that overlie part of the Windimurra Igneous Complex. The Niobe Rb-Li Project consists of 195-ha mining lease application over part of the Dalgaranga-Mount Farmer pegmatite swarm located approximately 70 km northwest of Mount Magnet. The Narndee Project covers a large portion of the ultramafic zone of the Narndee Igneous Complex. The Kameelburg Project is located in Namibia, Southwest Africa.

Aura Energy Limited

AEE

Aura Energy Ltd. engages in the exploration and evaluation of uranium, vanadium and gold and base metals in Mauritania and Sweden. The company is headquartered in Melbourne, Western Australia. The company went IPO on 2006-05-30. The firm is engaged in exploration and evaluation of uranium, vanadium and gold and base metals in Mauritania and Sweden. The firm is focused on uranium production commencing at the Tiris Project, a greenfield uranium discovery in Mauritania. The company holds 125 square kilometers of virgin Greenstone belt and is located approximately 36 kilometers south of the Kinross 20 Moz Tasiast Mine. Its Haggan deposit is located in Berg municipality in the province of Jamtland in central Sweden. The Haggan Project is a poly-metallic deposit containing economically significant levels of vanadium, sulphate of potash, nickel, zinc, and molybdenum. The company holds a 100% direct interest in the deposit. Its subsidiaries include Vanadis Battery Metals AB, Aura Energy Mauritania Pty Ltd, Tiris Ressources SA, Tiris International Mining Company sarl and others.

Ausmon Resources Limited

AOA

Ausmon Resources Ltd. is an exploration company, which focuses on gold, silver, copper and other base metals. The company is headquartered in Sydney, New South Wales. The company went IPO on 2009-03-31. The firm is engaged in exploration of minerals tenements with a focus on gold, silver, copper, cobalt, nickel, zinc, rare earth elements and other base metals. The Company’s New South Wales exploration licenses include EL 8745 (Kanbarra), EL 8747 (Stirling Vale), EL 9220 (Enmore), EL 9224 (Eureka), EL 9230 (Mt Darling), EL8954 (Brungle Creek) and EL 9252 (McAlpine). Its South Australia exploration license includes EL 6795 (Parrakie), EL 6796 (Mt Rough), EL 6797 (Kingston) and EL 6807 (Wolseley). Its Western Australia exploration licenses include EL 38/3718 (Barneys) and EL 38/3719 (Neckersgat). Its New South Wales exploration licenses covers an area of approximately 791 square kilometers (km2). Its South Australia exploration license covers an area of approximately 3,549 km2 in the Limestone Coast Region south-east of Adelaide within the Loxton Sands or equivalent of the Murray and Otway Basins.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.